Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esophageal artery infusion chemotherapy plus apatinib for advanced esophageal carcinoma after radiochemotherapy failure
ChiCTR1800016882Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in esophageal cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: overall survival, disease control rate and 1 more. Started Jun 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR1800016882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800016882.